A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (NCT05572515)
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Who can join: Review the eligibility criteria below.
Location: Alaska Oncology and Hematology LLC — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (211 Sites)
Showing the first 25 of 211 sites.
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Alta Bates Comprehensive Cancer Center — Berkeley, California
- MemorialCare Long Beach Medical Center — Long Beach, California
- University of California Irvine — Orange, California
- PIH Health Hospital — Whittier, California
- Rocky Mountain Cancer Centers — Aurora, Colorado
- University of Connecticut — Farmington, Connecticut
- University of Miami Sylvester Cancer Center — Miami, Florida
- Orlando Health Cancer Institute — Orlando, Florida
- Cleveland Clinic Florida — Weston, Florida
- Mission Cancer Blood — Waukee, Iowa
- East Jefferson General Hospital Bone Marrow Transport Clinic — Metairie, Louisiana
- Walter Reed National Military Medical Center — Bethesda, Maryland
- Maryland Oncology Hematology P A — Silver Spring, Maryland
- Boston University Medical Center — Boston, Massachusetts
- Saint Lukes Hospital Saint Lukes Cancer Specialists — Chesterfield, Missouri
- Cooper Health System MD Anderson Cancer Center at Cooper — Camden, New Jersey
- Herbert Irving Comprehensive Cancer Center Columbia University Medical Center — New York, New York
- Durham VAMC — Durham, North Carolina
- Penn Medicine Lancaster General Health — Lancaster, Pennsylvania
- Tennessee Oncology — Nashville, Tennessee
- Brooke Army Medical Center — Fort Sam Houston, Texas
- Baylor College of Medicine — Houston, Texas
- Michael E DeBakey VA Medical Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed or Refractory Multiple Myeloma
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) — Mobile, Alabama
- A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma — Toronto, Ontario
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma — Tucson, Arizona
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
- A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Relapsed or Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.